Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,193 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Syngeneic animal models of tobacco-associated oral cancer reveal the activity of in situ anti-CTLA-4.
Wang Z, Wu VH, Allevato MM, Gilardi M, He Y, Luis Callejas-Valera J, Vitale-Cross L, Martin D, Amornphimoltham P, Mcdermott J, Yung BS, Goto Y, Molinolo AA, Sharabi AB, Cohen EEW, Chen Q, Lyons JG, Alexandrov LB, Gutkind JS. Wang Z, et al. Nat Commun. 2019 Dec 5;10(1):5546. doi: 10.1038/s41467-019-13471-0. Nat Commun. 2019. PMID: 31804466 Free PMC article.
Microneedle-mediated Intratumoral Delivery of Anti-CTLA-4 Promotes cDC1-dependent Eradication of Oral Squamous Cell Carcinoma with Limited irAEs.
Gilardi M, Saddawi-Konefka R, Wu VH, Lopez-Ramirez MA, Wang Z, Soto F, Ramms DJ, Proietto M, Mikulski Z, Miki H, Sharabi A, Kupor D, Rueda R, Hollern DP, Wang J, Gutkind JS. Gilardi M, et al. Mol Cancer Ther. 2022 Apr 1;21(4):616-624. doi: 10.1158/1535-7163.MCT-21-0234. Mol Cancer Ther. 2022. PMID: 35086958 Free PMC article.
Lymphatic-preserving treatment sequencing with immune checkpoint inhibition unleashes cDC1-dependent antitumor immunity in HNSCC.
Saddawi-Konefka R, O'Farrell A, Faraji F, Clubb L, Allevato MM, Jensen SM, Yung BS, Wang Z, Wu VH, Anang NA, Msari RA, Schokrpur S, Pietryga IF, Molinolo AA, Mesirov JP, Simon AB, Fox BA, Bui JD, Sharabi A, Cohen EEW, Califano JA, Gutkind JS. Saddawi-Konefka R, et al. Nat Commun. 2022 Jul 25;13(1):4298. doi: 10.1038/s41467-022-31941-w. Nat Commun. 2022. PMID: 35879302 Free PMC article.
Germline modifiers of the tumor immune microenvironment implicate drivers of cancer risk and immunotherapy response.
Pagadala M, Sears TJ, Wu VH, Pérez-Guijarro E, Kim H, Castro A, Talwar JV, Gonzalez-Colin C, Cao S, Schmiedel BJ, Goudarzi S, Kirani D, Au J, Zhang T, Landi T, Salem RM, Morris GP, Harismendy O, Patel SP, Alexandrov LB, Mesirov JP, Zanetti M, Day CP, Fan CC, Thompson WK, Merlino G, Gutkind JS, Vijayanand P, Carter H. Pagadala M, et al. Among authors: wu vh. Nat Commun. 2023 May 12;14(1):2744. doi: 10.1038/s41467-023-38271-5. Nat Commun. 2023. PMID: 37173324 Free PMC article.
The GPCR-Gαs-PKA signaling axis promotes T cell dysfunction and cancer immunotherapy failure.
Wu VH, Yung BS, Faraji F, Saddawi-Konefka R, Wang Z, Wenzel AT, Song MJ, Pagadala MS, Clubb LM, Chiou J, Sinha S, Matic M, Raimondi F, Hoang TS, Berdeaux R, Vignali DAA, Iglesias-Bartolome R, Carter H, Ruppin E, Mesirov JP, Gutkind JS. Wu VH, et al. Nat Immunol. 2023 Aug;24(8):1318-1330. doi: 10.1038/s41590-023-01529-7. Epub 2023 Jun 12. Nat Immunol. 2023. PMID: 37308665 Free PMC article.
4E-BP1 Is a Tumor Suppressor Protein Reactivated by mTOR Inhibition in Head and Neck Cancer.
Wang Z, Feng X, Molinolo AA, Martin D, Vitale-Cross L, Nohata N, Ando M, Wahba A, Amornphimoltham P, Wu X, Gilardi M, Allevato M, Wu V, Steffen DJ, Tofilon P, Sonenberg N, Califano J, Chen Q, Lippman SM, Gutkind JS. Wang Z, et al. Among authors: wu x, wu v. Cancer Res. 2019 Apr 1;79(7):1438-1450. doi: 10.1158/0008-5472.CAN-18-1220. Epub 2019 Mar 20. Cancer Res. 2019. PMID: 30894372 Free PMC article.
1,193 results